Study Summary
Administering subretinal injection of LX107 injection (a gene therapy drug) to patients with retinal dystrophy caused by AIPL1 gene mutation to evaluate its efficacy and safety.
Want to learn more about this trial?
Request More InfoInterventions
LX107 InjectionGENETIC
Subjects will receive subretinal injection of LX107 on Day 0.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Shanghai | China |